StreetInsider.com News Articles

Form 425 Nano Dimension Ltd. Filed by: Nano Dimension Ltd.

Mon, 15 Jun 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26644307.html

Form 425 Nano Dimension Ltd. Filed by: Nano Dimension Ltd.

Mon, 15 Jun 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26644307.html

Form 425 Nano Dimension Ltd. Filed by: Nano Dimension Ltd.

Mon, 15 Jun 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26644307.html

Form DEFA14A Nano Dimension Ltd.

Mon, 15 Jun 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26644308.html

Form DEFA14A Nano Dimension Ltd.

Mon, 15 Jun 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26644308.html

Form DEFA14A Nano Dimension Ltd.

Mon, 15 Jun 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26644308.html

Form 8-K Nano Dimension Ltd. For: Jun 15

Mon, 15 Jun 2026 07:48:00 -0400

si-local-file:///var/storage/secattach/20260615/26644295.html

Form 8-K Nano Dimension Ltd. For: Jun 15

Mon, 15 Jun 2026 07:48:00 -0400

si-local-file:///var/storage/secattach/20260615/26644295.html

Form 8-K Nano Dimension Ltd. For: Jun 15

Mon, 15 Jun 2026 07:48:00 -0400

si-local-file:///var/storage/secattach/20260615/26644295.html

Nano Dimension signs term sheet to merge with Infinite Epigenetics for $890M

Mon, 15 Jun 2026 07:28:54 -0400

Nano Dimension Ltd. (NASDAQ: NNDM) announced it entered into a non-binding term sheet for a business combination with Infinite Epigenetics, an artificial intelligence-powered preventive health and diagnostics company. The transaction values Infinite Epigenetics at $890 million.

Under the proposed structure, Nano Dimension would acquire 100% of Infinite Epigenetics through a merger or similar transaction. The combined company would operate under the Infinite Epigenetics name and trade on Nasdaq under the proposed ticker "IEAI."

Existing Nano Dimension shareholders would retain a minority ownership interest in the combined company based on a stated value that reflects a 20% premium to Nano Dimension's estimated net

Nano Dimension signs term sheet to merge with Infinite Epigenetics for $890M

Mon, 15 Jun 2026 07:28:54 -0400

Existing Nano Dimension shareholders would retain a minority ownership interest in the combined company based on a stated value that reflects a 20% premium to Nano Dimension's estimated net

Nano Dimension signs term sheet to merge with Infinite Epigenetics for $890M

Mon, 15 Jun 2026 07:28:54 -0400

Existing Nano Dimension shareholders would retain a minority ownership interest in the combined company based on a stated value that reflects a 20% premium to Nano Dimension's estimated net

Nano Dimension signs term sheet to merge with Infinite Epigenetics for $890M

Mon, 15 Jun 2026 07:28:54 -0400

Existing Nano Dimension shareholders would retain a minority ownership interest in the combined company based on a stated value that reflects a 20% premium to Nano Dimension's estimated net

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity

Nano Dimension Signs Term Sheet with Infinite Epigenetics to Form a Publicly Traded, AI-Powered Preventive Health and Diagnostics Company

Mon, 15 Jun 2026 07:27:00 -0400

Nano Dimension Conducted a Rigorous Multi-Month Strategic Review, Assessing Approximately 20 Companies Before Selecting Infinite Epigenetics as the Most Compelling Path to Long-Term Value Creation
Proposed Combination Would Deploy Nano Dimension’s Capital Base and Nasdaq listing into a High-Growth Healthcare AI Opportunity
Existing Nano Shareholders Expected to Retain Meaningful Minority Ownership in Combined Company on a Stated Value for Nano Dimension’s Shares that Reflects a 20% Premium to Nano Dimension’s Estimated Net Cash at Closing
Infinite Epigenetics Transaction Value of $890 million
Infinite Epigenetics Targets a $90B+ U.S. Clinical Diagnostics Market Opportunity